240 related articles for article (PubMed ID: 6299634)
1. Effects of deoxyadenosine on the activation of ADA inhibited T & B cells.
Webster AD; Ip H; Pereira S
Clin Exp Immunol; 1982 Dec; 50(3):587-95. PubMed ID: 6299634
[TBL] [Abstract][Full Text] [Related]
2. Differential production of deoxyadenosine by human T and B lymphoblasts.
Iizasa T; Kubota M; Carson DA
J Immunol; 1983 Oct; 131(4):1776-9. PubMed ID: 6352803
[TBL] [Abstract][Full Text] [Related]
3. 2'Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells.
Ruers TJ; Buurman WA; van der Linden CJ
J Immunol; 1987 Jan; 138(1):116-22. PubMed ID: 3097141
[TBL] [Abstract][Full Text] [Related]
4. Characterization of an adenosine deaminase-deficient human histiocytic lymphoma cell line (DHL-9) and selection of mutants deficient in adenosir kinase and deoxycytidine kinase.
Kubota M; Kamatani N; Daddona PE; Carson DA
Cancer Res; 1983 Jun; 43(6):2606-10. PubMed ID: 6303563
[TBL] [Abstract][Full Text] [Related]
5. Consequences of adenosine deaminase deficiency on thymocyte metabolism.
Thuillier L; Garreau F; Cartier PH
Eur J Immunol; 1981 Oct; 11(10):788-94. PubMed ID: 6975717
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
Bontemps F; Van den Berghe G
Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493
[TBL] [Abstract][Full Text] [Related]
7. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RNA synthesis by deoxyadenosine plus deoxycoformycin in resting lymphocytes.
Matsumoto SS; Yu J; Yu AL
J Immunol; 1983 Dec; 131(6):2762-6. PubMed ID: 6196398
[TBL] [Abstract][Full Text] [Related]
9. Human B lymphocytes and thymocytes but not peripheral blood mononuclear cells accumulate high dATP levels in conditions simulating ADA deficiency.
Goday A; Simmonds HA; Morris GS; Fairbanks LD
Biochem Pharmacol; 1985 Oct; 34(19):3561-9. PubMed ID: 3876835
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
Lee N; Russell N; Ganeshaguru K; Jackson BF; Piga A; Prentice HG; Foa R; Hoffbrand AV
Br J Haematol; 1984 Jan; 56(1):107-19. PubMed ID: 6231047
[TBL] [Abstract][Full Text] [Related]
11. Differential inhibition of adenosine deaminase deficient peripheral blood lymphocytes and lymphoid line cells by deoxyadenosine and adenosine.
Hirschhorn R; Bajaj S; Borkowsky W; Kowalski A; Hong R; Rubinstein A; Papageorgiou P
Cell Immunol; 1979 Feb; 42(2):418-23. PubMed ID: 311698
[No Abstract] [Full Text] [Related]
12. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
Ratech H; Kim J; Asofsky R; Thorbecke GJ; Hirschhorn R
J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of adenosine deaminase-deficient human T cell lines.
Kohn DB; Mitsuya H; Ballow M; Selegue JE; Barankiewicz J; Cohen A; Gelfand E; Anderson WF; Blaese RM
J Immunol; 1989 Jun; 142(11):3971-7. PubMed ID: 2497184
[TBL] [Abstract][Full Text] [Related]
14. Deoxyadenosine modulates human suppressor T cell function and B cell differentiation stimulated by Staphylococcus aureus protein A.
Cohen AH; Bluestein HG; Redelman D
J Immunol; 1984 Apr; 132(4):1761-6. PubMed ID: 6199411
[TBL] [Abstract][Full Text] [Related]
15. Resistance of pokeweed mitogen-stimulated B cells to inhibition by deoxyadenosine.
Hayward AR
Clin Exp Immunol; 1980 Jul; 41(1):141-9. PubMed ID: 6969149
[TBL] [Abstract][Full Text] [Related]
16. Increased adenosine deaminase (ADA) activity and a shift from ADA-dependent to ADA-independent phases during T-cell activation: a paradox.
Veit BC; Fishman M; Look T
J Natl Cancer Inst; 1984 May; 72(5):1151-9. PubMed ID: 6609265
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
[No Abstract] [Full Text] [Related]
18. Enzyme replacement and other biochemical approaches to the therapy of adenosine deaminase deficiency.
Polmar SH
Ciba Found Symp; 1978; (68):213-30. PubMed ID: 227649
[TBL] [Abstract][Full Text] [Related]
19. Rejection of bone marrow transplant and resistance of alloantigen reactive cells to in vivo deoxyadenosine in adenosine deaminase deficiency.
Cowan MJ; Shannon KM; Wara DW; Ammann AJ
Clin Immunol Immunopathol; 1988 Nov; 49(2):242-50. PubMed ID: 2971490
[TBL] [Abstract][Full Text] [Related]
20. Role of adenosine deaminase in lymphocyte proliferation.
Hovi T; Smyth JF; Allison AC; Williams SC
Clin Exp Immunol; 1976 Mar; 23(3):395-403. PubMed ID: 133008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
